Deprecated: Creation of dynamic property PL_VBP_License::$version is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/license-page.php on line 92

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170

Deprecated: Creation of dynamic property Vidbg_WPBakery::$vc_row_atts is deprecated in /var/www/healingmaps.imarkdev.com/wp-content/plugins/video-background-pro/inc/classes/vidbg_wpbakery.php on line 49
ketamine therapy - Page 15 of 27 - HealingMaps

The Hidden Receptor Behind Ketamine’s Power

This discovery around ketamine's brain mechanism trigger holds promise for refining ketamine treatments for more effective treatments.

Read More

Johns Hopkins Recommends Key Safety Measures for Psychedelic Research

Johns Hopkins Medicine recommends psychedelics research guidelines. And is leading efforts to refine key areas of psychedelic research.

Read More

The American Society of Anesthesiologists’ Call for Ketamine Treatment Oversight

The American Society of Anesthesiologists issued guidance around the proper ans safe use of ketamine treatments.

Read More

Ketamine Shows Promise for Severe Obsessive-Compulsive Disorder in New Study

A recent study has uncovered promising findings regarding ketamine as a treatment for severe obsessive-compulsive disorder (OCD).

Read More

The Power of Group Dynamics in Psychedelic Therapy

A growing body of research suggests that psychedelics can do more than just alter perception—they can deepen human connections.

Read More

UVA Receives $9.3 Million Grant to Study Ketamine’s Potential in Preventing Epileptic Seizures

(UVA) has received a $9.3 million grant from the NIH to study ketamine as a potential treatment for status epilepticus.

Read More

FDA Approves Standalone Use of Johnson & Johnson’s Spravato for Depression

The FDA has expanded the approval of Johnson & Johnson's nasal spray, Spravato, for standalone use in treating major depressive disorder.

Read More

Low-Dose Ketamine Improves Brain Network Integrity in Depression Patients

In this study, low-dose ketamine led to significant improvements in mood and cognition within just a few hours of treatment.

Read More

Wisconsin Medicaid Now Covers Ketamine Therapy for Depression

Starting January 1st, Wisconsin Medicaid will cover IV ketamine therapy for major depressive disorder, including cases with suicidality.

Read More

CNN Ketamine FlashDoc: How a party drug could become a lifesaving antidepressant

The death of “Friends” star Matthew Perry has put ketamine under the spotlight. This CNN ketamine flashdoc dives into this emerging therapy.

Read More